Structural and functional imaging in parkinsonian syndromes.

Magnetic Resonance Techniques Applied to the Diagnosis and Treatment of Parkinson's Disease. Front Neurol (2015) 0.79

Combining Diffusion Tensor Imaging and Susceptibility Weighted Imaging on the Substantia Nigra of 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP)-induced Rhesus Monkey Model of Parkinson's Disease. West Indian Med J (2016) 0.75

Invited commentary on "Structural and functional imaging in parkinsonian syndromes". Radiographics (2014) 0.75

Beyond the midbrain atrophy: wide spectrum of structural MRI finding in cases of pathologically proven progressive supranuclear palsy. Neuroradiology (2017) 0.75

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56

Diagnostic criteria for Parkinson disease. Arch Neurol (1999) 11.65

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82

Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70

Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27

Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92

Parkinson's disease. First of two parts. N Engl J Med (1998) 5.90

A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med (1995) 4.44

Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25

Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 3.14

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86

Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2006) 2.77

Dementia with Lewy bodies. Lancet Neurol (2004) 2.66

Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain (2002) 2.35

Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology (2000) 2.19

New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology (2005) 2.14

Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord (2000) 2.10

Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology (2007) 2.09

Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain (2004) 2.06

Multiple system atrophy. Lancet Neurol (2004) 2.04

Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci (2003) 2.03

The diagnosis of Parkinson's disease. Lancet Neurol (2006) 1.97

Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med (2009) 1.90

Clinicopathological correlations in corticobasal degeneration. Ann Neurol (2011) 1.86

Multiple system atrophy: an update. Lancet Neurol (2009) 1.77

Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol (2001) 1.67

The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol (1999) 1.66

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology (2001) 1.65

Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med (2007) 1.60

FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage (2005) 1.40

Olivopontocerebellar atrophy: MR diagnosis and relationship to multisystem atrophy. Radiology (1990) 1.38

Brain amyloid imaging. J Nucl Med (2011) 1.35

Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology (2005) 1.33

Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol (2004) 1.33

Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol (2008) 1.30

SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med (2011) 1.28

Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry (1998) 1.25

MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. AJNR Am J Neuroradiol (2004) 1.23

Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord (2010) 1.22

Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med (1998) 1.22

Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord (2009) 1.13

Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol (2000) 1.13

Imaging approaches to Parkinson disease. J Nucl Med (2010) 1.12

Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase (2005) 1.07

Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med (1998) 1.06

Corticobasal degeneration as a cognitive disorder. Mov Disord (2003) 1.05

[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord (2000) 0.98

Imaging of corticobasal degeneration syndrome. Neuroradiology (2007) 0.96

Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. J Neuropsychiatry Clin Neurosci (2001) 0.94

Hyperintense putaminal rim sign is not a hallmark of multiple system atrophy at 3T. AJNR Am J Neuroradiol (2005) 0.94

Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am (2010) 0.92

Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology (2013) 0.92

Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord (2006) 0.91

SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol (2000) 0.90

Improving the diagnostic accuracy in parkinsonism: a three-pronged approach. Pract Neurol (2012) 0.88

Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement (2008) 0.88

Diagnosis and differential diagnosis of Parkinson's disease and parkinsonism. Parkinsonism Relat Disord (2000) 0.86

Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci (2003) 0.86

18F-FDG PET study on the idiopathic Parkinson's disease from several parkinsonian-plus syndromes. Parkinsonism Relat Disord (2012) 0.85

Diagnosis and management of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry (2002) 0.83

Assessment of Parkinson's disease with imaging. Parkinsonism Relat Disord (2007) 0.79

Metabolic impairment of brain metabolism in patients with Lewy body dementia. Eur J Neurol (2003) 0.79

Semiquantitative analysis of brain metabolism in patients with paraneoplastic neurologic syndromes. Clin Nucl Med (2013) 0.78

Signal changes of superior cerebellar peduncle on fluid-attenuated inversion recovery in progressive supranuclear palsy. Parkinsonism Relat Disord (2007) 0.78

Movement disorders: role of imaging in diagnosis. J Magn Reson Imaging (2012) 0.78

Extrapyramidal syndromes: PET and SPECT. Neuroimaging Clin N Am (2010) 0.77

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20

Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71

[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc (2013) 2.64

Brain β-amyloid load approaches a plateau. Neurology (2013) 2.50

Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. Brain (2012) 2.29

Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol (2013) 2.03

Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology (2012) 2.01

A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med (2008) 1.95

Thyroid cancer detection with dual-isotope parathyroid scintigraphy in primary hyperparathyroidism. Ann Surg Oncol (2012) 1.71

Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.65

Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol (2005) 1.60

NEMA NU 2-2001 performance measurements of an LYSO-based PET/CT system in 2D and 3D acquisition modes. J Nucl Med (2006) 1.56

Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT. AJR Am J Roentgenol (2006) 1.53

Risk of hematoma following needle electromyography of the paraspinal muscles. Muscle Nerve (2011) 1.46

Septation of the anorectal and genitourinary tracts in the human embryo: crucial role of the catenoidal shape of the urorectal sulcus. Teratology (2002) 1.44

Conditional signaling by Toll-like receptor 4. FASEB J (2005) 1.42

Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging (2011) 1.40

Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT. J Comput Assist Tomogr (2007) 1.38

Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging (2010) 1.37

Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors. Skeletal Radiol (2009) 1.35

In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. Mol Imaging Biol (2006) 1.30

Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann Neurol (2012) 1.28

NEMA NU 2-2007 performance measurements of the Siemens Inveon preclinical small animal PET system. Phys Med Biol (2009) 1.22

Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. JAMA Neurol (2013) 1.20

Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med (2007) 1.19

Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. Neurology (2013) 1.19

The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest (2007) 1.16

Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants. Arch Neurol (2010) 1.14

Evidence-based guideline: neuromuscular ultrasound for the diagnosis of carpal tunnel syndrome. Muscle Nerve (2012) 1.12

Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor. Mol Imaging Biol (2006) 1.12

Distinct regional anatomic and functional correlates of neurodegenerative apraxia of speech and aphasia: an MRI and FDG-PET study. Brain Lang (2013) 1.09

Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol (2013) 1.06

The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun (2007) 1.05

Targeting B lymphocytes in progressive fibrosing mediastinitis. Am J Respir Crit Care Med (2014) 1.04

Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis. Chest (2009) 1.04

The sensitivity of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of metastatic pulmonary nodules. Eur J Cardiothorac Surg (2008) 1.04

Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography. Lab Invest (2013) 1.03

The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma (2008) 1.02

PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR Am J Roentgenol (2012) 1.02

North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2010) 1.01

FDG PET/CT in patients with HIV. AJR Am J Roentgenol (2011) 0.99

Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol (2011) 0.99

Value of PET/CT in the management of liver metastases, part 1. AJR Am J Roentgenol (2011) 0.98

Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nucl Med (2014) 0.98

Percutaneous cryoablation of musculoskeletal oligometastatic disease for complete remission. J Vasc Interv Radiol (2012) 0.97

FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimer's type. PLoS One (2013) 0.96

T-cell neurolymphomatosis involving cauda equina and sciatic nerves. Neurology (2009) 0.96

Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts. Head Neck (2008) 0.96

Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol (2012) 0.95

Laterality errors in radiology reports generated with and without voice recognition software: frequency and clinical significance. J Am Coll Radiol (2013) 0.95

Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum (2005) 0.95

Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc (2008) 0.94

The utility of 11C-choline PET/CT for imaging prostate cancer: a pictorial guide. AJR Am J Roentgenol (2011) 0.94

Elevated occipital β-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. J Neurol Neurosurg Psychiatry (2013) 0.94

Oncologic 18F-FDG PET/CT: referring physicians' point of view. J Nucl Med (2012) 0.93

MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. Neurology (2013) 0.91

Positron emission tomography for basal cell carcinoma of the head and neck. Arch Dermatol (2003) 0.91

Diffuse cerebral vasospasm after resection of a posterior fossa ependymoma. Neurocrit Care (2011) 0.91

The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol (2012) 0.91

Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. Neurology (2013) 0.91

Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects? Neuroimage Clin (2013) 0.89

A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brain. PLoS One (2011) 0.89

Visual assessment versus quantitative three-dimensional stereotactic surface projection fluorodeoxyglucose positron emission tomography for detection of mild cognitive impairment and Alzheimer disease. Clin Nucl Med (2012) 0.88

Benign fibrous dysplasia on [(11)C]choline PET: a potential mimicker of disease in patients with biochemical recurrence of prostate cancer. Ann Nucl Med (2012) 0.88

Endobronchial ultrasound and lymphoproliferative disorders: a retrospective study. Ann Thorac Surg (2012) 0.88

The stripe of primary lateral sclerosis: focal primary motor cortex hypometabolism seen on fluorodeoxyglucose F18 positron emission tomography. Arch Neurol (2010) 0.87

18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid (2008) 0.87

Pulmonary nodule characterization, including computer analysis and quantitative features. J Thorac Imaging (2015) 0.87

Lung cancer screening experience: a retrospective review of PET in 22 non-small cell lung carcinomas detected on screening chest CT in a high-risk population. AJR Am J Roentgenol (2005) 0.86

Clinical, FDG and amyloid PET imaging in posterior cortical atrophy. J Neurol (2015) 0.86

Frequency of eye deviation in stroke and non-stroke patients undergoing head CT. Neurocrit Care (2012) 0.85

Clinical 18F-FDG oncology patient preparation techniques. J Nucl Med Technol (2003) 0.84

Malignant involvement of the peripheral nervous system in patients with cancer: multimodality imaging and pathologic correlation. Radiographics (2014) 0.83

The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma. J Nucl Med (2012) 0.83

Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study. Neurology (2013) 0.83

Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy. Parkinsonism Relat Disord (2010) 0.83

Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 0.83

18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun (2007) 0.83

Pulmonary embolism outcome: a prospective evaluation of CT pulmonary angiographic clot burden score and ECG score. AJR Am J Roentgenol (2008) 0.82

Utility of baseline positron emission tomography with computed tomography for predicting endoscopic resectability and survival outcomes in patients with early esophageal adenocarcinoma. J Gastroenterol Hepatol (2013) 0.81

Toll-like receptor-4 and allograft responses. Transplantation (2004) 0.81

Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Res (2017) 0.80

Use of IV epinephrine for treatment of patients with contrast reactions: lessons learned from a 5-year experience. AJR Am J Roentgenol (2009) 0.80

Effect of patient age, breast density, and topical anesthetic cream on perceived pain with sentinel lymph node scintigraphy. J Nucl Med Technol (2012) 0.80

Diagnostic imaging in paraneoplastic autoimmune multiorgan syndrome: retrospective single site study and literature review of 225 patients. Int J Dermatol (2014) 0.79

Metallopanstimulin as a marker for head and neck cancer. World J Surg Oncol (2004) 0.79

Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies. Nucl Med Commun (2011) 0.79